 SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 GLOBE NEWSWIRE -- Satsuma Pharmaceuticals, Inc. Nasdaq: STSA, a clinical-stage biopharmaceutical company developing STS101 dihydroergotamine DHE nasal powder, a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in one-on-one meetings with investors. The Conference will be held virtually with all participants joining remotely from September 13th 15th. 